Overview

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and to assess the T-cell response.

Phase:

Phase 1

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

Bristol-Myers Squibb
Fibrolamellar Cancer Foundation

Treatments:

Antibodies
Ipilimumab
Nivolumab
Poly ICLC
Vaccines